Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study

Mohammed Albalawi, Syed Ziauddin Ahmed Zaidi, Nawal AlShehry, Ahmed AlAskar, Abdul Rehman Zia Zaidi, Rania Nagib Mohammed Abdallah, Abdul Salam, Ahmed AlSagheir, Nour AlMozain, Ghada Elgohary, Khalid Batarfi, Alia Alfaraedi, Osamah Khojah, Rehab Al-Ansari, Mona Alfaraj, Afra Dayel, Ahmed Al Bahrani, Arwa Nabhan Abdelhameed, Hind Alhumaidan, Jawaher M Al-Otaibi, Ghazala Radwi, Abdulrahman Raizah, Hind Shatry, Sara Alsaleh, Hazzaa AlZahrani, Hani Al-Hashmi, Mohammed Albalawi, Syed Ziauddin Ahmed Zaidi, Nawal AlShehry, Ahmed AlAskar, Abdul Rehman Zia Zaidi, Rania Nagib Mohammed Abdallah, Abdul Salam, Ahmed AlSagheir, Nour AlMozain, Ghada Elgohary, Khalid Batarfi, Alia Alfaraedi, Osamah Khojah, Rehab Al-Ansari, Mona Alfaraj, Afra Dayel, Ahmed Al Bahrani, Arwa Nabhan Abdelhameed, Hind Alhumaidan, Jawaher M Al-Otaibi, Ghazala Radwi, Abdulrahman Raizah, Hind Shatry, Sara Alsaleh, Hazzaa AlZahrani, Hani Al-Hashmi

Abstract

Background: The COVID-19 pandemic is expected to cause significant morbidity and mortality. The development of an effective vaccine will take several months to become available, and its affordability is unpredictable. Transfusion of convalescent plasma (CP) may provide passive immunity. Based on initial data from China, a group of hematologists, infectious disease specialists, and intensivists drafted this protocol in March 2020.

Objective: The aim of this study is to test the feasibility, safety, and efficacy of CP in treating patients with COVID-19 across Saudi Arabia.

Methods: Eligible patients with COVID-19 will be recruited for CP infusion according to the inclusion criteria. As COVID-19 has proven to be a moving target as far as its management is concerned, we will use current definitions according to the Ministry of Health (MOH) guidelines for diagnosis, treatment, and recovery. All CP recipients will receive supportive management including all available recommended therapies according to the available MOH guidelines. Eligible CP donors will be patients with COVID-19 who have fully recovered from their disease according to MOH recovery criteria as detailed in the inclusion criteria. CP donors have to qualify as blood donors according to MOH regulations except for the history of COVID-19 in the recent past. We will also test the CP donors for the presence of SARS-CoV-2 antibodies by a rapid test, and aliquots will be archived for future antibody titration. Due to the perceived benefit of CP, randomization was not considered. However, we will compare the outcome of the cohort treated with CP with those who did not receive CP due to a lack of consent or lack of availability. In this national collaborative study, there is a likelihood of not finding exactly matched control group patients. Hence, we plan to perform a propensity score matching of the CP recipients with the comparator group patients for the major characteristics. We plan to collect demographic, clinical, and laboratory characteristics of both groups and compare the outcomes. A total sample size of 575 patients, 115 CP recipients and 460 matched controls (1:4 ratio), will be sufficient to detect a clinically important hospital stay and 30-day mortality difference between the two groups with 80% power and a 5% level of significance.

Results: At present, patient recruitment is still ongoing, and the interim analysis of the first 40 patients will be shared soon.

Conclusions: In this paper, we present a protocol for a national collaborative multicenter phase II study in Saudi Arabia for assessing the feasibility, safety, and potential efficacy of CP in treating patients with severe COVID-19. We plan to publish an interim report of the first 40 CP recipients and their matched comparators soon.

Trial registration: ClinicalTrials.gov NCT04347681; https://ichgcp.net/clinical-trials-registry/NCT04347681.

International registered report identifier (irrid): PRR1-10.2196/23543.

Keywords: COVID-19; SARS-CoV-2; antibodies; convalescent plasma; coronaviruses; efficacy; feasibility; immunology; infectious disease; safety; treatment.

Conflict of interest statement

Conflicts of Interest: None declared.

©Mohammed Albalawi, Syed Ziauddin Ahmed Zaidi, Nawal AlShehry, Ahmed AlAskar, Abdul Rehman Zia Zaidi, Rania Nagib Mohammed Abdallah, Abdul Salam, Ahmed AlSagheir, Nour AlMozain, Ghada Elgohary, Khalid Batarfi, Alia Alfaraedi, Osamah Khojah, Rehab Al-Ansari, Mona Alfaraj, Afra Dayel, Ahmed Al Bahrani, Arwa Nabhan Abdelhameed, Hind Alhumaidan, Jawaher M Al-Otaibi, Ghazala Radwi, Abdulrahman Raizah, Hind Shatry, Sara Alsaleh, Hazzaa AlZahrani, Hani Al-Hashmi. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 02.10.2020.

Figures

Figure 1
Figure 1
Some therapeutic options for treating COVID-19.
Figure 2
Figure 2
Logistic cycle of convalescent plasma procurement from donor, processing, and infusion to patient with COVID-19. IgG: immunoglobulin G; IgM: immunoglobulin M.
Figure 3
Figure 3
Schematic for the proposed process of CP donation and infusion. CP: convalescent plasma; PCR: polymerase chain reaction.

References

    1. World Health Organization Middle East respiratory syndrome coronavirus (MERS-CoV) Krankenhaushyg Infektionsverhut. 2014 Mar;36(1):34–35. doi: 10.1016/j.khinf.2014.01.014.
    1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020. China CDC Weekly. 2020;2(8):113–22. doi: 10.46234/ccdcw2020.032.
    1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8.
    1. COVID-19 coronavirus pandemic. Worldometer. 2020. [2020-04-02].
    1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR, Convalescent Plasma Study Group The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 01;211(1):80–90. doi: 10.1093/infdis/jiu396.
    1. Hung IF, To KK, Lee C, Lee K, Chan K, Yan W, Liu R, Watt C, Chan W, Lai K, Koo C, Buckley T, Chow F, Wong K, Chan H, Ching C, Tang BS, Lau CC, Li IW, Liu S, Chan K, Lin C, Yuen K. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011 Feb 15;52(4):447–56. doi: 10.1093/cid/ciq106.
    1. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016 Mar;14(2):152–7. doi: 10.2450/2015.0131-15.
    1. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Ströher U, Crozier I, Sacra R, Connor MJ, Sueblinvong V, Franch HA, Smith PW, Ribner BS, Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015 Aug 15;61(4):496–502. doi: 10.1093/cid/civ334.
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28; doi: 10.1093/cid/ciaa344.
    1. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020 May 05;172(9):577–582. doi: 10.7326/M20-0504.
    1. Diagnosis and treatment protocol for COVID-19 (trial version 7) National Health Commission of the People's Republic of China. [2020-04-04]. .
    1. Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–8. doi: 10.1172/jci138003.
    1. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Yu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Z XX, Yang X. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. 2020 Mar 16;:6145. doi: 10.1101/2020.03.16.20036145.
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398–400. doi: 10.1016/s1473-3099(20)30141-9.
    1. Investigational COVID-19 convalescent plasma - emergency INDs. U.S. Food And Drug Administration. 2020. Mar 25, [2020-04-04]. .
    1. COVID-19 convalescent plasma collection: donor eligibility, processing, labeling, and distribution. American Association of Blood Banks. 2020. Apr 04, [2020-04-04]. .
    1. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465–469. doi: 10.1038/s41586-020-2196-x.
    1. COVID-19 Investigation Team Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020 Jun;26(6):861–868. doi: 10.1038/s41591-020-0877-5.
    1. Hornsey V, Drummond O, Morrison A, McMillan L, MacGregor I, Prowse C. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion. 2009 Oct;49(10):2167–72. doi: 10.1111/j.1537-2995.2009.02272.x.
    1. Larrea L, Calabuig M, Roldán V, Rivera J, Tsai H, Vicente V, Roig R. The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci. 2009 Dec;41(3):199–204. doi: 10.1016/j.transci.2009.09.006.
    1. Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion. 2010 Apr;50(4):926–31. doi: 10.1111/j.1537-2995.2009.02517.x.
    1. Norfolk D, editor. Handbook of Transfusion Medicine, fifth edition. UK: TSO Information & Publishing Solutions; 2013. The ABO system.
    1. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E, Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. Convalescent plasma treatment of severe COVID-19: a matched control study. medRxiv. 2020 May 20;:2236. doi: 10.1101/2020.05.20.20102236.
    1. Plasma For COVID. .

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit